Sinil Pharmaceutical Co. Ltd - Asset Resilience Ratio
Sinil Pharmaceutical Co. Ltd (012790) has an Asset Resilience Ratio of 17.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Sinil Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. Check 012790 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sinil Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 012790 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩29.67 Billion | 17.46% |
| Total Liquid Assets | ₩29.67 Billion | 17.46% |
Asset Resilience Insights
- Good Liquidity Position: Sinil Pharmaceutical Co. Ltd maintains a healthy 17.46% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Sinil Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Sinil Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Sinil Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Sinil Pharmaceutical Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.31% | ₩33.69 Billion ≈ $22.83 Million |
₩165.86 Billion ≈ $112.40 Million |
+4.96pp |
| 2023-12-31 | 15.35% | ₩23.41 Billion ≈ $15.86 Million |
₩152.46 Billion ≈ $103.32 Million |
-0.97pp |
| 2022-12-31 | 16.32% | ₩23.31 Billion ≈ $15.80 Million |
₩142.83 Billion ≈ $96.79 Million |
+0.16pp |
| 2021-12-31 | 16.16% | ₩20.84 Billion ≈ $14.12 Million |
₩128.97 Billion ≈ $87.40 Million |
+4.48pp |
| 2020-12-31 | 11.68% | ₩14.57 Billion ≈ $9.88 Million |
₩124.81 Billion ≈ $84.58 Million |
+0.17pp |
| 2019-12-31 | 11.50% | ₩13.56 Billion ≈ $9.19 Million |
₩117.84 Billion ≈ $79.86 Million |
-1.32pp |
| 2018-12-31 | 12.83% | ₩13.65 Billion ≈ $9.25 Million |
₩106.40 Billion ≈ $72.11 Million |
-0.10pp |
| 2017-12-31 | 12.93% | ₩13.25 Billion ≈ $8.98 Million |
₩102.52 Billion ≈ $69.48 Million |
-1.86pp |
| 2016-12-31 | 14.79% | ₩14.50 Billion ≈ $9.83 Million |
₩98.05 Billion ≈ $66.45 Million |
-2.98pp |
| 2015-12-31 | 17.77% | ₩15.51 Billion ≈ $10.51 Million |
₩87.26 Billion ≈ $59.14 Million |
-0.66pp |
| 2014-12-31 | 18.43% | ₩14.73 Billion ≈ $9.98 Million |
₩79.91 Billion ≈ $54.15 Million |
-- |
About Sinil Pharmaceutical Co. Ltd
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more